Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Prime Medicine's Prime Editing Is Worth The Risk
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts
182,133 Shares in Prime Medicine, Inc. $PRME Acquired by DNB Asset Management AS
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Drink Group Announces Management Change
Prime Medicine to Participate in Upcoming Investor Conferences
Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of “Moderate Buy” from Brokerages
Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options
Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Brokerages
Prime Drink Group Announces Private Placement
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
Cortexyme (NASDAQ:CRTX) vs. Prime Medicine (NYSE:PRME) Critical Review
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript
Prime Medicine to Present at Jefferies Global Healthcare Conference
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer